[{"id":"941b1153-fb94-4360-9c39-d0685da9af97","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393509","created_at":"2021-01-18T05:43:22.326Z","updated_at":"2024-07-02T16:35:52.184Z","phase":"Phase 1","brief_title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01393509","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" JAK2 • CD4","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelavespib intravenous (PU-H71 IV)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/06/2011","start_date":" 07/06/2011","primary_txt":" Primary completion: 03/23/2023","primary_completion_date":" 03/23/2023","study_txt":" Completion: 03/23/2023","study_completion_date":" 03/23/2023","last_update_posted":"2023-03-28"},{"id":"2b53c85f-055b-4401-b086-8ffe8c25b04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03166085","created_at":"2021-01-18T15:36:35.642Z","updated_at":"2024-07-02T16:36:19.332Z","phase":"Phase 1b","brief_title":"PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer","source_id_and_acronym":"NCT03166085","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • zelavespib intravenous (PU-H71 IV)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 12/14/2021","primary_completion_date":" 12/14/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2021-12-20"}]